CO2017009954A2 - Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina - Google Patents
Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúminaInfo
- Publication number
- CO2017009954A2 CO2017009954A2 CONC2017/0009954A CO2017009954A CO2017009954A2 CO 2017009954 A2 CO2017009954 A2 CO 2017009954A2 CO 2017009954 A CO2017009954 A CO 2017009954A CO 2017009954 A2 CO2017009954 A2 CO 2017009954A2
- Authority
- CO
- Colombia
- Prior art keywords
- repeats
- designed
- binding specificity
- ankyrine
- domains
- Prior art date
Links
- 102000007562 Serum Albumin Human genes 0.000 title abstract 2
- 108010071390 Serum Albumin Proteins 0.000 title abstract 2
- 102000023732 binding proteins Human genes 0.000 abstract 5
- 108091008324 binding proteins Proteins 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 abstract 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 abstract 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15162502 | 2015-04-02 | ||
| EP15162511 | 2015-04-02 | ||
| PCT/EP2016/057272 WO2016156596A1 (en) | 2015-04-02 | 2016-04-01 | Designed ankyrin repeat domains with binding specificity for serum albumin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017009954A2 true CO2017009954A2 (es) | 2018-02-20 |
Family
ID=55650423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0009954A CO2017009954A2 (es) | 2015-04-02 | 2017-09-29 | Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9458211B1 (enExample) |
| EP (2) | EP3277711B9 (enExample) |
| JP (1) | JP6552636B2 (enExample) |
| KR (2) | KR20220109488A (enExample) |
| CN (1) | CN107454904A (enExample) |
| AU (3) | AU2016240220B2 (enExample) |
| BR (1) | BR112017020986A2 (enExample) |
| CA (1) | CA2979602C (enExample) |
| CL (1) | CL2017002454A1 (enExample) |
| CO (1) | CO2017009954A2 (enExample) |
| ES (1) | ES2953482T3 (enExample) |
| IL (2) | IL276944B (enExample) |
| MX (2) | MX2022008302A (enExample) |
| MY (1) | MY179505A (enExample) |
| NZ (1) | NZ735803A (enExample) |
| PH (1) | PH12017501792B1 (enExample) |
| RU (1) | RU2769470C2 (enExample) |
| SA (1) | SA517390092B1 (enExample) |
| SG (1) | SG11201707606RA (enExample) |
| WO (1) | WO2016156596A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2643469T3 (es) | 2006-04-07 | 2017-11-23 | Aerpio Therapeutics, Inc. | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos |
| CN103459415B (zh) * | 2010-11-26 | 2021-04-09 | 分子组合公司 | 设计的与血清白蛋白结合的重复蛋白 |
| US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
| CA3030298A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | Humanized monoclonal antibodies that target ve-ptp (hptp-.beta.) |
| ES2953516T3 (es) * | 2016-09-22 | 2023-11-14 | Molecular Partners Ag | Proteínas de unión recombinantes y su uso |
| WO2019011167A1 (zh) * | 2017-07-12 | 2019-01-17 | 四川科伦博泰生物医药股份有限公司 | 双特异性重组蛋白 |
| WO2019034332A1 (en) * | 2017-08-18 | 2019-02-21 | Cambridge Enterprise Limited | MODULAR BINDING PROTEINS |
| CN120058958A (zh) | 2018-09-24 | 2025-05-30 | 视点制药公司 | 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体 |
| CN119930814A (zh) * | 2019-03-22 | 2025-05-06 | 反射制药有限公司 | 针对vegf的d-肽化合物 |
| US20220242973A1 (en) * | 2019-06-04 | 2022-08-04 | Molecular Partners Ag | Recombinant fap binding proteins and their use |
| KR20220016944A (ko) | 2019-06-04 | 2022-02-10 | 몰리큘라 파트너스 아게 | 개선된 안정성을 갖는 설계된 안키린 반복 도메인 |
| CA3139041A1 (en) | 2019-06-04 | 2020-12-10 | Christian REICHEN | Recombinant 4-1bb binding proteins and their use |
| CA3139051A1 (en) | 2019-06-04 | 2020-12-10 | Christian REICHEN | Multispecific proteins |
| WO2021116462A1 (en) * | 2019-12-11 | 2021-06-17 | Molecular Partners Ag | Designed ankyrin repeat domains with altered surface residues |
| US20230041822A1 (en) | 2019-12-11 | 2023-02-09 | Molecular Partners Ag | Recombinant peptide-mhc complex binding proteins and their generation and use |
| TW202208404A (zh) | 2020-05-06 | 2022-03-01 | 瑞士商分子組合公司 | 新穎錨蛋白重複結合蛋白質及其用途 |
| BR112022023049A2 (pt) | 2020-05-14 | 2022-12-20 | Molecular Partners Ag | Proteínas multiespecíficas |
| EP4149960A1 (en) * | 2020-05-14 | 2023-03-22 | Molecular Partners AG | Recombinant cd40 binding proteins and their use |
| EP3957649A1 (en) | 2020-08-18 | 2022-02-23 | Athebio AG | Improved n-terminal capping modules of ankyrin repeat domains |
| JP2023554351A (ja) * | 2020-12-16 | 2023-12-27 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規の徐放性プロドラッグ |
| AU2021403658A1 (en) | 2020-12-16 | 2023-06-29 | Molecular Partners Ag | Recombinant cd3 binding proteins and their use |
| AU2022231913A1 (en) | 2021-03-09 | 2023-09-28 | Molecular Partners Ag | Novel darpin based cd33 engagers |
| US20240150475A1 (en) | 2021-03-09 | 2024-05-09 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| JP2024509890A (ja) | 2021-03-09 | 2024-03-05 | モレキュラー パートナーズ アクチェンゲゼルシャフト | プロテアーゼ切断可能なプロドラッグ |
| JP2024509904A (ja) | 2021-03-09 | 2024-03-05 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規なＤＡＲＰｉｎに基づく多重特異性Ｔ細胞エンゲージャ |
| WO2023110983A1 (en) | 2021-12-14 | 2023-06-22 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
| CN114957426B (zh) * | 2022-06-02 | 2023-05-16 | 华南师范大学 | Sp6rars及其在防治蜚蠊目昆虫中的应用 |
| CN119731200A (zh) | 2022-08-01 | 2025-03-28 | 分子合作伙伴股份公司 | 经电荷修饰设计的重复结构域及其用途 |
| WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
| AR131869A1 (es) | 2023-02-17 | 2025-05-07 | Ablynx Nv | POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL |
| WO2024179981A1 (en) | 2023-02-27 | 2024-09-06 | Molecular Partners Ag | Darpins for use in reducing renal accumulation of drugs |
| WO2024251695A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd47 binding proteins and their use |
| WO2024251742A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd2 binding proteins and their use |
| WO2024251628A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd16a binding proteins and their use |
| WO2025073871A1 (en) | 2023-10-03 | 2025-04-10 | Bicycletx Limited | Bicyclic peptide ligand complexes specific for tfr1 |
| WO2025146487A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Multispecific binding proteins |
| WO2025146490A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Recombinant cd117 binding proteins and their use |
| WO2025146491A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent |
| WO2025163144A1 (en) | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Recombinant mesothelin binding proteins and their use |
| US20250332297A1 (en) | 2024-01-31 | 2025-10-30 | Molecular Partners Ag | Dll3-specific binding constructs and their use in radiotherapy |
| WO2025181039A1 (en) | 2024-03-01 | 2025-09-04 | Molecular Partners Ag | Therapeutic combinations comprising a multi-specific t cell engager |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| JP5291279B2 (ja) | 2000-09-08 | 2013-09-18 | ウニヴェルジテート・チューリッヒ | 反復モジュールを含む反復タンパク質の集合体 |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| BRPI0517834A (pt) | 2004-11-12 | 2008-10-21 | Bayer Schering Pharma Ag | vìrus da doença de newcastle recombinante |
| EP2949668B1 (en) | 2005-05-18 | 2019-08-14 | Ablynx N.V. | Improved nanobodies tm against tumor necrosis factor-alpha |
| DE602006010386D1 (en) | 2005-07-08 | 2009-12-24 | Univ Zuerich | Phagen-display mittels cotranslationaler translokation von fusionspolypeptiden |
| WO2007103515A2 (en) | 2006-03-06 | 2007-09-13 | Amunix, Inc. | Unstructured recombinant polymers and uses thereof |
| ATE502114T1 (de) | 2007-06-21 | 2011-04-15 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
| WO2009040338A1 (en) | 2007-09-24 | 2009-04-02 | University Of Zürich | Designed armadillo repeat proteins |
| WO2010060748A1 (en) * | 2008-11-03 | 2010-06-03 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
| CA2788993A1 (en) | 2010-02-05 | 2011-08-11 | Ablynx N.V. | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
| WO2012004384A2 (en) * | 2010-07-09 | 2012-01-12 | Affibody Ab | Polypeptides |
| JP2013537522A (ja) * | 2010-07-19 | 2013-10-03 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗癌治療への応答可能性の増大した患者を同定する方法 |
| EP2853542A1 (en) | 2010-11-24 | 2015-04-01 | Glaxo Group Limited | Multispecific antigen binding proteins targeting HGF |
| CN103459415B (zh) | 2010-11-26 | 2021-04-09 | 分子组合公司 | 设计的与血清白蛋白结合的重复蛋白 |
| WO2012149439A2 (en) | 2011-04-29 | 2012-11-01 | Janssen Biotech, Inc. | Il4/il13 binding repeat proteins and uses |
| BR112014032316A2 (pt) | 2012-06-28 | 2017-06-27 | Molecular Partners Ag | proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| US11453708B2 (en) * | 2013-05-31 | 2022-09-27 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
-
2016
- 2016-04-01 AU AU2016240220A patent/AU2016240220B2/en not_active Ceased
- 2016-04-01 EP EP16713904.7A patent/EP3277711B9/en active Active
- 2016-04-01 NZ NZ735803A patent/NZ735803A/en not_active IP Right Cessation
- 2016-04-01 US US15/089,014 patent/US9458211B1/en active Active
- 2016-04-01 MX MX2022008302A patent/MX2022008302A/es unknown
- 2016-04-01 ES ES16713904T patent/ES2953482T3/es active Active
- 2016-04-01 MX MX2017012485A patent/MX393655B/es unknown
- 2016-04-01 PH PH1/2017/501792A patent/PH12017501792B1/en unknown
- 2016-04-01 EP EP23177745.9A patent/EP4272838A3/en active Pending
- 2016-04-01 WO PCT/EP2016/057272 patent/WO2016156596A1/en not_active Ceased
- 2016-04-01 KR KR1020227025940A patent/KR20220109488A/ko not_active Ceased
- 2016-04-01 SG SG11201707606RA patent/SG11201707606RA/en unknown
- 2016-04-01 KR KR1020177030096A patent/KR102427117B1/ko active Active
- 2016-04-01 CA CA2979602A patent/CA2979602C/en active Active
- 2016-04-01 BR BR112017020986-1A patent/BR112017020986A2/pt not_active Application Discontinuation
- 2016-04-01 MY MYPI2017703637A patent/MY179505A/en unknown
- 2016-04-01 CN CN201680019907.XA patent/CN107454904A/zh active Pending
- 2016-04-01 RU RU2017134456A patent/RU2769470C2/ru active
- 2016-04-01 IL IL276944A patent/IL276944B/en unknown
- 2016-04-01 JP JP2017551176A patent/JP6552636B2/ja active Active
- 2016-08-26 US US15/248,731 patent/US10155791B2/en active Active
-
2017
- 2017-09-28 CL CL2017002454A patent/CL2017002454A1/es unknown
- 2017-09-28 IL IL254788A patent/IL254788B/en active IP Right Grant
- 2017-09-29 CO CONC2017/0009954A patent/CO2017009954A2/es unknown
- 2017-10-02 SA SA517390092A patent/SA517390092B1/ar unknown
-
2018
- 2018-11-02 US US16/178,923 patent/US11332501B2/en active Active
-
2020
- 2020-02-21 AU AU2020201264A patent/AU2020201264A1/en not_active Abandoned
-
2021
- 2021-12-17 AU AU2021286418A patent/AU2021286418B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017009954A2 (es) | Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina | |
| CO2019002609A2 (es) | Proteínas de unión recombinantes y sus usos | |
| CL2020002043A1 (es) | Métodos y composiciones para la entrega de proteínas terapeuticas. | |
| UY35407A (es) | ?PROTEÍNAS DE FUSIÓN COMPRENDIENDO PORCIONES PDGF y VEGF DE UNIÓN Y MÉTODOS PARA SU USO?. | |
| MX2017010117A (es) | Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso. | |
| MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
| GEP20227447B (en) | Constructs having sirp-alpha domain or variant thereof | |
| MX392683B (es) | Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso. | |
| BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
| EA201491644A1 (ru) | Фармацевтические композиции | |
| BR112019001737A2 (pt) | expressão de pten-long com vírus oncolíticos | |
| BR112017015567A2 (pt) | proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica | |
| EA201792047A1 (ru) | Новые соединения | |
| MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
| MX376324B (es) | Proteinas de union a desmogelina 2 (dsg2) y usos de los mismos. | |
| BR112017014615A2 (pt) | proteínas de fusão de multi-direcionamento e seus usos | |
| MX359201B (es) | Polipeptidos que se unen al complemento humano 5 (c5). | |
| MX2021004533A (es) | Metodos para el analisis de la composicion de la proteina de la capside viral. | |
| MX2021014649A (es) | Dominio de repetición de anquirina diseñado con estabilidad mejorada. | |
| CO2017011583A2 (es) | Polipéptidos dirigidos a la fusión de vih | |
| DK3399040T3 (da) | Fremgangsmåde til fremstilling af porcine circovirus type 2 capsid-protein og farmaceutisk sammensætning omfattende samme | |
| BR112017000710A2 (pt) | polipeptídeo isolado, polipeptídeo modificado de revestimento final isolado, composição de matéria, polipeptídeo de fusão isolado, composição farmacêutica, método de tratamento de uma doença inflamatória, uso do polipeptídeo isolado, polinucleotídeo isolado, estrutura de ácido nucleico, e método de determinação da potência de um lote do polipeptídeo isolado | |
| EP3956350C0 (en) | MODIFIED CRY PROTEINS FOR DELIVERY OF THERAPEUTIC AGENTS | |
| BR112019005959A2 (pt) | gene dgkk recombinante para terapia genética da síndrome do x frágil | |
| BR112017004008A2 (pt) | polipeptídeo recombinante, sequência de ácido nucleico, célula hospedeira, bionanopartícula, métodos para produção de uma bionanopartícula e para tratamento ou prevenção do vírus da dengue, e, vacina. |